A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

• Published in: Clinical ophthalmology (Auckland, N.Z.) Vol. 15; pp. 3889 - 3900
• Main Authors: McMullin, David, Clark, David, Cavanagh, Bill, Karpecki, Paul, Brady, Todd C
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Anti-inflammatory agents; Antibiotics; Care and treatment; Chronic illnesses; Clinical trials; Comparative analysis; Demographics; Drug dosages; dry eye disease; Eye diseases; eye drop comfort; FDA approval; Immunosuppressive agents; Inflammation; lifitegrast; Ophthalmic drugs; Original Research; Patient compliance; Patients; Quality of life; rasp inhibitor; reproxalap; Taste disorders; United States > US; reproxalap; lifitegrast; RASP inhibitor; dry eye disease; eye drop comfort; inflammation

To assess the subjective eye drop experience of patients with dry eye disease (DED) over approximately 1 hour after a single dose of two formulations of reproxalap versus lifitegrast. Two formulations of topical ocular reproxalap 0.25% were evaluated versus lifitegrast ophthalmic solution 5% in pati...